Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent
September 25 2019 - 08:00AM
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced that the United States Patent and Trademark
Office has issued a patent with claims related to the Company’s
proprietary liposomal delivery and antisense technology, DNAbilize,
including its use in the treatment of cancers, autoimmune diseases
and infectious diseases. This is the second U.S. patent
issued for the Company’s platform technology.
The new patent, United States Patent No. 10,335,428 (based on
Application No. 15/657,083), titled “P-Ethoxy Nucleic Acids for
Liposomal Formulation,” which issued July 2, 2019, provides
additional claims for the broad protection previously granted in
Patent No. US 9,744,187 (issued August 29, 2017) for application of
the DNAbilize technology in the treatment of a variety of cancers,
as well as autoimmune and infectious diseases. DNAbilize is a
proprietary liposomal nanoparticle delivery and antisense
technology designed to systemically distribute nucleic acid drugs
throughout the human body with a simple intravenous
transfusion.
Bio-Path’s platform technology patents allow the Company to
develop new drug product candidates using its proprietary DNAbilize
technology. As new drug product candidates are developed
using DNAbilize technology, new patent applications can be filed
for the specific drug products incorporating DNAbilize
technology.
Applying the DNAbilize technology to a protein target can result
in a specific drug product for which a new DNAbilize drug product
patent application can be filed. The Company anticipates that
the number of DNAbilize drug product candidates will increase
significantly in the coming years.
The Company believes its patented platform technology provides a
powerful template with the capability to produce a large portfolio
of patented drug products. The Company currently has two
issued platform technology patents for DNAbilize and five pending
patent applications for specific DNAbilize drug product candidates.
Each of the issued technology platform patents has a life of twenty
years from filing, and any issued patents for specific DNAbilize
drug products will also be protected for twenty years from
filing.
Consequently, the Company expects its expanding intellectual
property estate for DNAbilize to be a source of both exciting
breakthroughs in cancer therapy and to be an engine for
out-licensing opportunities across a broad spectrum of cancer
indications with currently unmet medical needs.
“Our strategy is to leverage the value of our patented DNAbilize
technology by focusing on our mission to develop systemic DNAbilize
treatments for hard-to-treat diseases. In doing so, we
believe we can develop multiple drug products that can enhance
shareholder value through partnering or licensing at various stages
of drug product development. This will allow Bio-Path to
focus on the front-end of the development process, while partnering
out development through later stages of clinical development,” said
Peter Nielsen, President and Chief Executive Officer of Bio-Path
Holdings.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study for the
treatment of blood cancers and is in the process of filing an IND
for a Phase 1 clinical trial for solid tumors. The Company is also
developing BP1002, which targets the Bcl-2 protein and is expected
to be evaluated for the treatment of lymphoma and solid tumors. In
addition, BP1003, a novel liposome-incorporated STAT3 antisense
oligodeoxynucleotide developed by Bio-Path as a specific inhibitor
of STAT3, is expected to enter Phase 1 studies in 2020.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws. These statements are based on management's current
expectations and accordingly are subject to uncertainty and changes
in circumstances. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Any statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including
Bio-Path’s ability to raise needed additional capital on a timely
basis in order for it to continue its operations, Bio-Path's
ability to have success in the clinical development of its
technologies, the timing of enrollment and release of data in such
clinical studies and the accuracy of such data, limited patient
populations of early stage clinical studies and the possibility
that results from later stage clinical trials with much larger
patient populations may not be consistent with earlier stage
clinical trials, the maintenance of intellectual property rights,
that patents relating to existing for future patent applications
will be issued or that any issued patents will provide meaningful
protection of our drug candidates, risks relating to maintaining
Bio-Path's listing on the Nasdaq Capital Market and such other
risks which are identified in Bio-Path's most recent Annual Report
on Form 10- K, in any subsequent quarterly reports on Form 10-Q and
in other reports that Bio-Path files with the Securities and
Exchange Commission from time to time. These documents are
available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2023 to Mar 2024